256 related articles for article (PubMed ID: 33593422)
1. Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.
Benmalek R; Mechal H; Zahidi H; Mounaouir K; Arous S; Benouna MEG; Drighil A; Habbal R
J Med Case Rep; 2021 Feb; 15(1):76. PubMed ID: 33593422
[TBL] [Abstract][Full Text] [Related]
2. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
5. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.
Abdulkarim K; Samuelsson J; Johansson P; Andréasson B
Eur J Haematol; 2017 Jun; 98(6):577-583. PubMed ID: 28251679
[TBL] [Abstract][Full Text] [Related]
9. Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Wen H; Jin D; Chen Y; Cui B; Xiao T
BMC Neurol; 2021 Jun; 21(1):225. PubMed ID: 34134639
[TBL] [Abstract][Full Text] [Related]
10. Vertebral artery thrombosis: a rare presentation of primary polycythaemia.
Gul HL; Lau SY; Chan-Lam D; Ng JP
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24862411
[TBL] [Abstract][Full Text] [Related]
11. The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature.
Jacobs J; Sharma D; Vnencak-Jones C
J Thromb Thrombolysis; 2022 Jan; 53(1):213-217. PubMed ID: 34240279
[TBL] [Abstract][Full Text] [Related]
12. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
13. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
14. ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.
Duran Luciano P; Sabella-Jiménez V
Tex Heart Inst J; 2023 Oct; 50(5):. PubMed ID: 37872693
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Cerebral Venous Thrombosis and Intracranial Hemorrhages in Presentation of a Patient with Secondary Polycythemia: A Case Report.
Fahrurriza H; Gofir A; Setyawan TR; Hutajulu SH; Nugroho DB; Ar Rochmah M
Am J Case Rep; 2023 Oct; 24():e941507. PubMed ID: 37838828
[TBL] [Abstract][Full Text] [Related]
17. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Reikvam H; Tiu RV
Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.
Schafer AI
Blood; 2006 Jun; 107(11):4214-22. PubMed ID: 16484586
[TBL] [Abstract][Full Text] [Related]
20. Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Trifan G; Shafi N; Testai FD
J Stroke Cerebrovasc Dis; 2018 Oct; 27(10):2572-2578. PubMed ID: 30056970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]